v3.25.4
Segment Reporting - Schedule of Reconciliation of Segment Profits to Income Before Taxes (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]      
Sales $ 65,011 $ 64,168 $ 60,115
Cost of sales 16,382 15,193 16,126
Selling, general and administrative 10,733 10,816 10,504
Research and development 15,789 17,938 30,531
Other segment items 151 (24) 466
Income Before Taxes 21,067 19,936 1,889
Interest income 343 415 365
Interest expense (1,357) (1,271) (1,146)
Amortization (2,793) (2,395) (2,044)
Depreciation (3,045) (2,104) (1,828)
Research and development (15,789) (17,938) (30,531)
Restructuring costs (889) (309) (599)
Total segment profits      
Segment Reporting Information [Line Items]      
Sales 64,496 63,277 59,208
Income Before Taxes 47,885 46,471 40,617
Depreciation (287) (261) (203)
Total segment profits | Pharmaceutical      
Segment Reporting Information [Line Items]      
Sales 58,142 57,400 53,583
Cost of sales 6,679 6,828 8,849
Selling, general and administrative 5,874 6,128 5,903
Research and development 0 0 0
Other segment items (165) (89) (49)
Income Before Taxes 45,754 44,533 38,880
Depreciation (5) (5) (5)
Research and development 0 0 0
Total segment profits | Animal Health      
Segment Reporting Information [Line Items]      
Sales 6,354 5,877 5,625
Cost of sales 2,649 2,469 2,498
Selling, general and administrative 1,125 1,084 1,038
Research and development 448 385 353
Other segment items 1 1 (1)
Income Before Taxes 2,131 1,938 1,737
Depreciation (282) (256) (198)
Research and development (448) (385) (353)
Other profits      
Segment Reporting Information [Line Items]      
Sales 515 891 907
Research and development 14,987 17,350 30,008
Income Before Taxes 251 492 474
Interest income 343 415 365
Interest expense (1,357) (1,271) (1,146)
Amortization (2,793) (2,395) (2,044)
Depreciation (2,758) (1,843) (1,625)
Research and development (14,987) (17,350) (30,008)
Restructuring costs (889) (309) (599)
Charge for Zetia antitrust litigation settlements 0 0 (573)
Other unallocated, net $ (4,628) $ (4,274) $ (3,572)